
Granules India Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 22 Jan 2026 • 3:25 pm
Posted by:

Granules India' Q3 results FY26 are scheduled to be announced on 23rd January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Granules India Q3 Results 2026 Preview
- Granules India's revenue is expected to be in the range of ₹,137.70 crore, a 17.70% YoY increase.
- Profit After Tax, or PAT, is projected to rise by 20.95% YoY.
- Granules India's EBITDA is expected to rise to ₹173.68 crore.
- Net profit is ₹117.60 crore, up 20.95% YoY
Granules India Share Performance
- Over the past six months, Granules India's share price has fallen by 15.18% to ₹5.53.
- Moreover, over the past year, the stock has decreased by 23.83%.
- Despite this weak short-term performance, Granules India's stock has delivered a financially sound 1.25% return over the past 5 years.
- As of 22nd January 2026, the stock traded at ₹69.60 per share.
Key Factors to Watch for Granules India Q3 Results FY26
- Revenue & Segment Mix: Performance across APIs, PFIs and finished dosages, with focus on formulation-led growth.
- Margins & Profitability: EBITDA and PAT margin trends driven by product mix, pricing and cost efficiencies.
- Regulatory Updates: USFDA compliance status and any impact on exports and production continuity.
- Capacity Expansion & Pipeline: Progress on new facilities, ANDA approvals, and product launch outlook.
Final Thoughts
Granules India will announce its Q3 FY26 results on 23rd January 2026. Analysts expect 17.70% YoY revenue growth, a 20.95% rise in PAT, and an 15.18% rise in EBITDA. Granules India focuses on growing its integrated pharmaceutical business by expanding APIs, PFIs and finished dosage formulations, strengthening global (especially U.S.) exports, enhancing regulatory compliance and approvals, and scaling capacity through new plants and product launches.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
Recent Articles

Sensex Options Hit a Record Daily Premium Turnover in October 2026, Up 53% to Rs 35,481 Crore, as Volatility Returned to Indian Markets
2 November 2026

Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026

Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026

Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Sensex Options Hit a Record Daily Premium Turnover in October 2026, Up 53% to Rs 35,481 Crore, as Volatility Returned to Indian Markets
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





